Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice
M Villagrán-García, R Velasco - Neurological Sciences, 2022 - Springer
Neurological, immune-related adverse events (n-irAE) due to immune checkpoint inhibitors
(ICI) represent a growing clinical problem in neuro-oncology practice. Although rare, the …
(ICI) represent a growing clinical problem in neuro-oncology practice. Although rare, the …
Myasthenia gravis induced by immune checkpoint inhibitors: an emerging neurotoxicity in neuro-oncology practice: case series
C Marco, M Simó, M Alemany, C Casasnovas… - Journal of Clinical …, 2022 - mdpi.com
Immunotherapy with immune checkpoint inhibitors (ICIs) have been reported to induce de
novo or exacerbate pre-existing Myasthenia Gravis (MG). We present a single center case …
novo or exacerbate pre-existing Myasthenia Gravis (MG). We present a single center case …
Elaborating on anti CTLA-4 mechanisms of action using an agent-based modeling approach
Anti CTLA-4 therapy is aimed at blocking the Cytotoxic T-lymphocyte antigen-4 (CTLA-4), a
key cancer immunity cycle checkpoint. The mechanism of action of CTLA-4 may be …
key cancer immunity cycle checkpoint. The mechanism of action of CTLA-4 may be …
[HTML][HTML] 肿瘤免疫治疗毒性管理难点
关雅萍， 王俊 - 实用肿瘤杂志, 2022 - xml-data.org
以免疫检查点抑制剂为主的免疫治疗已经成为实体瘤治疗的主要手段, 广谱且有效,
改变了肿瘤治疗的格局, 但随之产生的毒性, 或称为免疫相关不良反应(immune-related adverse …
改变了肿瘤治疗的格局, 但随之产生的毒性, 或称为免疫相关不良反应(immune-related adverse …
Decreasing Readmission Rates in Patients With Immune-Mediated Toxicities Using an APRN-Led Discharge Teaching Program.
ML Rohlfs - Clinical Journal of Oncology Nursing, 2022 - search.ebscohost.com
Patients with cancer are at increased risk for readmission, which can be associated with
increased healthcare costs and poor patient outcomes, because of the nature of the disease …
increased healthcare costs and poor patient outcomes, because of the nature of the disease …
A novel necroptosis-related LncRNA signature for prediction of prognosis and therapeutic responses of head and neck squamous cell carcinoma
Z Meng, W Yang, L Zhu, W Liu, Y Wang - Frontiers in Pharmacology, 2022 - frontiersin.org
Background: Long non-coding RNAs (lncRNAs) play an essential role in the occurrence and
prognosis of tumors, and it has great potential as biomarkers of tumors. However, the roles …
prognosis of tumors, and it has great potential as biomarkers of tumors. However, the roles …